Why has the Atomo Diagnostics (ASX: AT1) share price surged 50% since Christmas?

Could this be why the company's stock has taken off lately?

The Atomo Diagnostics Ltd (ASX: AT1) share price has surged through the festive period. It's gained 50% since the ASX closed on Christmas Eve.

The stock's recent boost could be due to its involvement with COVID-19 rapid tests. Rapid tests have been the talk of the town lately as Australia faces a record wave of COVID-19 cases.

At the time of writing, the Atomo Diagnostic share price is 31.5 cents, 5% higher than its previous close.

For context, the S&P/ASX 200 Index (ASX: XJO) is up 1.3% right now.

Let's take a closer look at what might be driving the company's stock lately.

female nurse in scrubs

Image source: Getty Images

Atomo Diagnostics share price particularly festive

The Atomo Diagnostics share price has been on a roll lately. The company's shares surged 26% on Wednesday, triggering the ASX to issue a 'please explain'.

In its response, the company noted increased media attention on the topic of COVID rapid antigen tests. Indeed, rapid tests have been on many minds lately, including those of the country's decision-makers.

The same day the Atomo Diagnostics share price experienced its major leap, Prime Minister Scott Morrison announced the federal government was bringing forward a national cabinet meeting to discuss implications of the Omicron outbreak, including testing arrangements.

That meeting occurred on 30 December. It led to the introduction of new orders stating rapid antigen tests will become the go-to COVID-19 test for most Australians, with PCR tests restricted to those with symptoms and close contacts.

Additionally, Atomo Diagnostics pointed to an article published by the Sydney Morning Herald the previous day as a potential catalyst for its shares' gains.

The article discussed increasing demand from consumers and state governments for COVID-19 rapid tests.

In October, the company announced new terms to its supply agreement for COVID-19 rapid tests.

It can now purchase up to 10 million rapid tests to be used in professional settings in Australia and New Zealand and another 10 million to be sold commercially.

While the Atomo Diagnostics share price initially dived 11.7% on the new terms, the prospect of supplying more tests could be what's got the market excited about the company.

However, despite the stock's Christmas gains, the company's share price is only 1.6% higher than it was this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »